Increased serum pannexin-1 concentrations reflect illness severity and predict a poor prognosis after acute supratentorial intracerebral hemorrhage: A prospective longitudinal cohort study.

BACKGROUND: Pannexin-1 is a nonselective, large pore and voltage gated channel protein, whose activation may aggravate acute brain injury. We ascertained the clinical significance of serum pannexin-1 as a prognostic biomarker of acute intracerebral hemorrhage (ICH). METHODS: In this prospective, observational study of 124 acute supratentorial ICH patients and 124 healthy controls, serum pannexin-1 concentrations were determined. Admission National Institutes of Health Stroke Scale (NIHSS) score and hematoma volume were used for assessment of hemorrhagic severity, post-stroke 6-month modified Rankin scale (mRS) score was registered to reflect clinical outcome and early neurologic deterioration (END) and 6-month poor outcome (mRS score of 3-6) were regarded as the 2 prognostic parameters. Their associations with serum pannexin-1 concentrations were investigated using multivariate analysis. The predictive performance was evaluated in terms of area under receiver operating characteristic curve (AUC). RESULTS: In comparison to controls, significantly increased serum pannexin-1 concentrations after ICH (median, 6.8 vs. 2.7 mg/ml) were independently correlative with NIHSS score (ß, 0.193; 95% CI: 0.086-0.300), hematoma volume (ß, 0.641; 95% CI: 0.423-0.859) and mRS score (ß, 0.199; 95% CI: 0.065-0.174), were independently predictive of END (OR, 1.176; 95% CI: 1.081-1.280) and poor outcome (odds ratio, 1.218; 95% CI: 1.059-1.400), as well as were efficiently discriminative of END (AUC, 0.764; 95% CI: 0.663-0.864) and poor 6-month outcome (AUC, 0.790; 95% CI: 0.711-0.870). Serum pannexin-1 combined with NIHSS score and hematoma volume (AUC, 0.908; 95% CI: 0.857-0.960) displayed significantly higher predictive ability for poor 6-month outcome than NIHSS score and hematoma volume alone (both P < 0.05). CONCLUSION: Rising serum pannexin-1 concentrations following ICH, in strong correlation with hemorrhagic severity, independently distinguish the risk of END and 90-day poor outcome. Assumably, serum pannexin-1 may represent a valuable prognostic biomarker of ICH.

Serum Gas6 contributes to clinical outcome after aneurysmal subarachnoid hemorrhage: A prospective cohort study.

BACKGROUND: Growth-arrest-specific protein 6 (Gas6) exerts nervous protective effects on acute brain injury. We endeavored to ascertain whether serum Gas6 concentrations are associated with severity, delayed cerebral ischemia (DCI) and prognosis following aneurysmal subarachnoid hemorrhage (aSAH). METHODS: We measured serum Gas6 concentrations of 124 aSAH patients. The Hunt-Hess scale and modified Fisher grading scale were used to evaluate illness severity. Multivariate analysis was utilized to determine relationships between serum Gas6 concentrations and severity, DCI plus 90-day unfavorable outcome (Glasgow outcome scale score of 1-3). RESULTS: Patients with unfavorable outcome or DCI had significantly higher serum Gas6 concentrations than other remainders (median, 35.0 vs 23.3 ng/ml; 36.1 vs 25.3 ng/ml; both P < 0.001). Serum Gas6 concentrations displayed independent correlations with Hunt-Hess scores (t = 5.518, P < 0.001) and modified Fisher scores (t = 3.531, P = 0.001). Serum Gas6 concentrations were independently associated with unfavorable outcome (OR: 1.125; 95% CI, 1.063-1.190; P = 0.014) and DCI (OR: 1.104; 95% CI, 1.041-1.170; P = 0.010) as well as exhibited AUCs of 0.786 (95% CI, 0.703-0.854) and 0.753 (95% CI, 0.668-0.826) for predicting unfavorable outcome and DCI respectively. Its discriminatory ability for risk of unfavorable outcome or DCI was similar to those of Hunt-Hess scores and modified Fisher scores (all P > 0.05). CONCLUSIONS: Serum Gas6 concentrations are independently associated with stroke severity and worse clinical outcome after aSAH, indicating serum Gas6 may be a potential prognostic biomarker for aSAH.